639858-44-9Relevant articles and documents
NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS
-
Page/Page column 304; 305; 306, (2017/08/20)
The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF- KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
Discovery and evaluation of N-cyclopropyl-2,4-difluoro-5-((2-(pyridin-2- ylamino)thiazol-5-ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2
Borzilleri, Robert M.,Bhide, Rajeev S.,Barrish, Joel C.,D'Arienzo, Celia J.,Derbin, George M.,Fargnoli, Joseph,Hunt, John T.,Jeyaseelan Sr., Robert,Kamath, Amrita,Kukral, Daniel W.,Marathe, Punit,Mortillo, Steve,Qian, Ligang,Tokarski, John S.,Wautlet, Barri S.,Zheng, Xiaoping,Lombardo, Louis J.
, p. 3766 - 3769 (2007/10/03)
Substituted 3-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)-amino)benzamides were identified as potent and selective inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2) kinase activity. The enzyme kinetics associated with the VEGFR-2 inhibi